<DOC>
	<DOCNO>NCT00301808</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , pemetrexed disodium , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving one chemotherapy drug ( combination chemotherapy ) together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cisplatin pemetrexed disodium together radiation therapy follow docetaxel work treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin , Pemetrexed Disodium , Radiation Therapy Followed Docetaxel Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess 1-year survival stage III non-small cell lung cancer ( NSCLC ) patient treat cisplatin , pemetrexed disodium , concurrent thoracic radiotherapy follow consolidation therapy docetaxel . Secondary - Assess progression-free survival overall survival . - Assess toxicity regimen . OUTLINE : Patients receive pemetrexed disodium IV 10 minute follow cisplatin IV 60 minute day 1 . Treatment repeat every 21 day 3 course absence unacceptable toxicity . Patients also receive concurrent thoracic radiotherapy week 1-7 . Between 3-8 week completion chemoradiotherapy , patient progressive disease receive docetaxel IV 1 hour day 1 . Treatment docetaxel repeat every 21 day 3 course . After completion study therapy , patient follow 1 month periodically thereafter . PROJECTED ACCRUAL : A total 28 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic cytologic diagnosis nonsmall cell lung cancer ( NSCLC ) , meet 1 follow stag criterion : Stage IIIA disease , meet follow criterion : Mediastinal lymph node involvement Greater one mediastinal lymph node enlarge CT scan , confirm positron emission tomography ( PET ) scan Paralyzed leave vocal cord separate lung primary distinct aortopulmonary lymph node CT scan Stage IIIB disease , meet follow criterion : N3 lymph node involvement Enlarged N3 lymph node CT scan confirm PET scan Lymph node involvement may extend cervical lymph node supraclavicular lymph node Rightsided primary tumor leave vocal cord paralysis Evidence tumor extension mediastinum and/or mediastinal structure mediastinoscopy , bronchoscopy , CT scan No evidence malignant pleural effusion unless effusion evident CT scan No 1 parenchymal lesion opposite side lung No brain metastases CT scan MRI PATIENT CHARACTERISTICS : SWOG performance status 0 1 Platelet count ≥ 100,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 45 mL/min Bilirubin normal Transaminases ( SGOT and/or SGPT ) ≤ 1.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Total lung volume ( i.e. , right leave lung minus gross tumor volume ) receive great 20 Gy radiation ≤ 40 % FEV_1 ≥ 70 % predict DLCO ≥ 50 mL/min No concurrent malignancy Prior malignancy allow provided clinical control likely impact clinical outcome opinion treat physician No peripheral neuropathy ≥ grade 2 No serious medical illness , include , limited , follow : Uncontrolled congestive heart failure Uncontrolled angina Myocardial infarction Cerebrovascular event within past 6 month History chronic active hepatitis History HIV infection Active bacterial infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must willing able take folic acid , cyanocobalamin ( vitamin B12 ) , dexamethasone PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy NSCLC No concurrent participation another therapeutic investigational study Concurrent ibuprofen ( 400 mg four time daily ) allow pemetrexed disodium administration provide patient normal renal function No concurrent aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day , , 2 day pemetrexed disodium administration Patients longacting NSAIDs ( e.g . naproxen sodium , diflunisal , nabumetone , celecoxib ) must willing able discontinue usage 5 day prior , , 2 day pemetrexed disodium administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>